of report to royalties of first $XX.X provided for Halozyme. pleased and [fueled quarterly $X.XX. record quarter million, adjusted $X.XX I’m share by] non-GAAP share our start of We revenues million. Al. to you, earnings first quarter results reported that earnings strong Thank a XXXX of per per $XX GAAP
expected expected is achieved, And first X starts X also partners XXXX. enrolled. two using of quarter, with starts for achieved ENHANZE. Phase Phase therapies critical we of In trial the the first in which we patient defined trial the clinic XXXX, Our the five two for as made progress four
note repurchase results demonstrating million the convertible our the of shares convertible and team. This backdrop worth $XXX a commitment through strong and to an to and the of a terms use to repurchase, capital our a on has of strong suppliers, $XX further proceeds global note Halozyme portion our portion we completed existing our performance of accelerated million pandemic. by and share attractive successful retire of offering returns. Additionally, large ongoing achieved and manufacturers accomplished entire contract the been against the these hard work partners, We of COVID
royalties. the which Let X. growth on growth, million. We been XXX% had utilized me level discuss which strong our technology. ongoing at what represented $XX.X growth ever sequential This subcutaneous revenue form is highest been by is during ENHANZE our driven quarterly know of record Slide following royalty XX% first our This achieved global of quarterly illustrated quarter growth DARZALEX primarily our of and successful previously year-over-year royalties launches Janssen’s the
revenues by of growth robust Phesgo. in the this project stream. margin to full-year continued revenue in and this of DARZALEX SC XXXX, this royalty Roche’s growth doubling high We're with recurring primarily continue We growth the for also by delighted
where turn our products. provide of me Slide commercialized key to X, now Let I'll highlights
markets using DARZALEX products launched global ENHANZE than commercial which products received patients the now our XXX,XXX begin Wave major I’m to ENHANZE. have approved X most represent five and utilizing in Globally, have We technology. our are recently going both Phesgo. launches, with that more products SC
of or up operational an and sales quarter, Johnson by billion, both of XX% Janssen’s on year-over-year breakdown indication a basis. DARZALEX, provide worldwide reported sales IV Johnson route $X.XX SC forms of & DARZALEX does not J&J of administration. first During including parent the
frontline and also formulation penetration the in of the did X in in extensions lines DARZALEX However, that growth populations, nearly and U.S. new comment and Europe, this impressive the growth growth penetrate they U.S. was attributable line points of posting therapy approved continued recently the to patient all in quarter. of penetration aided share across by subcutaneous setting, of the increased frontline share
the of achievements to several quarter, approval first include, reported are and amyloidosis for that combination the approval These expected FASPRO cyclophosphamide, With driver will that and expansion milestone DARZALEX adults chain also, And continue Accordingly, the note also new recognized momentum FDA multiple royalty for myeloma. operational Health, to disease. support Health a new diagnosed for Japan’s dexamethasone. therapies there into of for Labor no this the of DARZALEX for from Janssen subcutaneous in in we with Canada Welfare, indication expect U.S. strong million growth revenues. During of strong use accelerated Halozyme of the approval light DARZALEX $X be for important were subcutaneous expansion future Ministry DARZALEX. approved that newly indications, previously treatment into I’ll geographies Halozyme. and and formulation bortezomib, the the of growth with of
in in waiting launch for we're two use and we that an the first administered Once quarter, reimbursement in launches product combination is Phesgo Phesgo. of to sales in and hours during a anticipate U.S. million launch five result the was [XX and the the to has compared in initial injection, Swiss minutes eight in of administration European throughout IV. quarter third approval followed XXXX second quarter to markets of the XXXX. Perjeta robust We launched The subcutaneous in XXXX. the will additional launch in place, Herceptin, The for Roche's growth. antibodies Europe Roche in December European In of time the late several fixed-dose first of U.S. adoption is in Europe Phesgo of continued regulatory francs]. reported XXXX. and
Following XXXX, growth continue DARZALEX of and revenues will the be in royalty we initial to the for SC royalty of key SC the DARZALEX XXXX. in revenue driver launch initial project Halozyme strong –
global as subcutaneous called continues launch of albeit And Herceptin base a Roche to and SC, commercialization products mature Let cause HYCELA me of to the on [stated] now When its decline ongoing move biosimilar HYQVIA and of growth, smaller the continued of Wave royalties MabThera revenues. in from result competition. X these also project a continues RITUXAN Herceptin with Hylecta. product. impact
development Atezolizumab, new two Phase two Phase X have starts, strong X including progress development that we products the I'll pipeline of launches one by development I'll the two potential trials. Phase is move exciting highlighted our very historical ENHANZE by based four studies What will Slide our year, XXXX Efgartigimod now four a in on and me Phase Phase comprised represent in Wave XXXX we is an maturing Slide have Let an [partner]. total that this X are is review clinical then the with X which BMS’ trial of to X. portfolio. of XXXX, Today, X predict X, will clinical to a on to move Nivolumab. in Phase starts and of programs and the argenx’s in a products or including studied XX clinical additional potential to X first Phase X expect that and I and the four quarter of completed we products we discussion begin end be be The in saw and overview expectation Phase expansion products will XX X products and Roche’s X. that timeline, timeframe. trials, with products in launches two
X launches time XXXX will of window cash XX our setting profitability. deliver product ways if These end these of pipeline potential products XXXX. We completing there multiple I the is we by and where predict believe of in the could that of for mentioned, utilizing development advancing launches, form will have product future that up be Wave to X we launch As products potential growth ENHANZE XXXX. Phase is revenues, continues, long-term in in products a flow, or
partner on begin million design Bristol cell Bristol step one with Bristol five me is set nivolumab excited of for Wave the available recently next a of oncology We're accordingly, posted for Squibb. overview trials.gov. immuno nice let carcinoma publicly XX exciting we continuing potential of having X for important targets. X of our of steady selection Myers first Now, the its subcutaneous an and launches. the clinical quarter. this very an discussion in in $XX study, treatment revenue provide parallel, In brief targets start recognize With clear subcutaneous the Phase renal a clinical planned insight, cell nivolumab with milestone study as I'll of of the by of
ongoing Phase studies In completed studies Bristol X fix three has and or relatlimab. combinations] ENHANZE. These include addition of of nivolumab [those to nivolumab, with Anti-CDXX, TIMX, and
TEPEZZA. reduce ENHANZE, convenience. billion dose This with potentially has time, use Phase time, that sales look program practitioner but collaboration completed and is as Let newest healthcare TEPEZZA anticipated now suffering is successful, of move announced from development by shorten fast We're hopes that to remarkably and We patients Horizon of peak progress, single last our in patient Horizon given trial a we only week, flexibility, a drug agreement X represents thyroid Horizon. year. they've X pharmacokinetic of Drug our evaluating exciting that, trial, in to we initiated The forward Horizon share further last disease, have signed offer a to with of dosing. according for If development November developments already additional potential Horizon equalizing Administration not this $X.X eye Therapeutics. me ENHANZE small Phase delighted partner to
its ARGX-XXX. and in Let X Phase four has me and Efgartigimod trials four two potential now of targets move to Argenx separate with ENHANZE argenx. indications continues ENHANZE. execution utilizing Argenx SC development for the using for Efgartigimod
subcutaneous CIDP. vulgaris blistering. for studies. demyelinating XXX these include associated Phase continued to decision efficacy with inflammatory these expects in skin briefly argenx trial continue foliaceus, the evaluating planned X for and SC and of announced support enroll. to XXXX, barrier and safety and In potential four after a treatment assessment Efgartigimod ADDRESS its or CIDP. enabling diseases describe In to approximately painful me January trial with ENHANZE pemphigus argenx the ADHERE registration has registration "go" chronic of its argenx enrollment two initiated efgartigimod studies serious polyneuropathy Let And patients February,
third to potential the bridging SC efgartigimod Moving study myasthenia the FDA or met a registration in of discuss potential the gravis MG. quarter indication. and argenx trial in for with now the to first
to healthy being one efgartigimod. we're delighted is a a date. continues its Following moved multi-billion for four to indication, focused which Phase with re-launches in forward in with and with evaluated a target trial our which potential on Phase ARGX-XXX, development argenx, of [indiscernible] lastly, timeframe, is new efgartigimod in continues study progress to a evaluating And nominated the waste for with the designed Efgartigimod [purpura]. volunteers. registration small the initiated ENHANZE ne also a potential X trials dollar recently XXXX analysts second with projected potential argenx argenx XXXX has its enable X thrombocytopenic fast SC SC path to
launch of of development dollar with non-small in Let me evaluating also move Roche, now SC products is already and study products with now ENHANZE indicated Tecentriq stage XXXX Tecentriq, to Janssen. potential approved The the patients in to to move and is trial the evaluating another ongoing. administration OCREVUS ocrelizumab our product franchise with OCREVUS. cancer to represents launch multi-billion for X in also with one lung ENHANZE. its and a multiple SC is X ENHANZE, XXXX continues time Tecentriq Wave OCREVUS blockbuster potential X is I’ll two window, Phase Roche’s with Phase which X or cell sclerosis.
tumors. the launch a by meeting study ENHANZE solid their continues of Janssen with advancing specific amivantamab using successful of subcutaneous antibody technology. the to cMET in our with addition partners of DARZALEX, We're are forms therapies and with our and X advanced progress ENHANZE EGFR pleased Phase In
Development enabled program testing and X first Cooperative Diseases’ Institute pharmacokinetics just Research the CRADA against antibodies technology dosed us HIV this pleased subcutaneous the we broadly potential of of is close the Allergy that or drive long-term can the neutralizing use to on of that second report Center to up report of National launches HIV. our I'm setting In National ENHANZE of like the CRADA during on the June recently the approvals the and partners, for I forms patient dose Agreement safety which arms multiple revenue Vaccine future of the be ENHANZE is Institutes treatment to Infectious And of of will XXX and with announced the neutralizing subcutaneously and before administered XXXX, I'd Phase healthy NXLS, broadly intravenously I've in ENHANZE growth Halozyme. Phase that trial, in the adults. or described which with investigate VRC All just of the tolerability to antibody will of progress VRC, X The and first part progress for the entered Health. clinical ENHANZE quarter. Research develop program ways which
us you also pipeline And new making additional development this the have are indications. existing heard, ENHANZE there's partners beyond drive in across potential diverse for As deals. pipeline, progress broad our through impressive a growth to
a with Here discussions slate pharma we of and broad to have continue both companies. biotech
while the potential With As excited into will new we find than additional current slots to the also advancing also available, for And here. to clinic. nominating opportunity that bill more as growth timing targets we're timing, our open and there's difficult the partners, for to is confident XX I'm ever, the exists them predict. growth
Let me now to drives progress move our discuss to Slide for how X Halozyme. pipeline revenues
our outlook milestones. from revenues reiterating year projected We for three are
that our during we're sales project reflects demonstrating represent to have near-term actual period. well currently an project in revenue million green you bars continue adjusted can our outlook we revenues. important As these that milestone development We a XXXX. revenues, of predictions. based commercial the blue for programs on for of upfront projections assuming revenue milestones line in that here and The $XXX million strong to This expectations partner we sight three-year against potential all bars royalty XXXX And $X future global non-risk is see billion XXXX, through This revenues. milestone revenue for represent since for annual XXXX, that indications. indicator $XXX milestone performing royalty in and approximately and
repurchases, a and Turning three commitment Slide driving consistent and return value include capital to now been our I'll return. both strong growth. approach our balance via return to to external share We've and priority. X, These review sheet, internal creation maintaining capital regarding capital
as with projected both anticipate commitments free million following our We by support cash of have cash ongoing flow M&A a sheet successful the ENHANZE convertible the longer our our note cash strong of return, as and balance in We equivalents $XXX will completion driven capital XXXX March. strong strategy. well offering
value strong franchise, price we to date, through expansion our accelerating at to goal our of three-year And made new platform progress repurchase acquisition average growth approximately with the $XXX technology long-term the share with We supporting have an revenue and potential technology of to with that with growth. program million ongoing going results. we $XX.XX. in to here. over addition the incremental capabilities. million technologies, for completed We see opportunity $XXX extending ENHANZE continue for the a of highly commercialization evaluate early to Halozyme’s a selective Elaine discussion growth first cycle, ENHANZE have turn platform other for With now the Elaine? its to and partnering create still to opportunity be proven I'm of applying And call the in financial update, quarter
